Use of antiretroviral therapy in pregnancy and association with birth outcome among women living with HIV in Denmark: A nationwide, population-based cohort study.
Danish HIV Birth Cohort
antiretroviral therapy
birth outcome
pregnancy
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
revised:
25
02
2022
received:
22
12
2021
accepted:
12
03
2022
pubmed:
8
4
2022
medline:
17
9
2022
entrez:
7
4
2022
Statut:
ppublish
Résumé
To describe antiretroviral therapy (ART) regimens during pregnancy among women living with HIV (WLWH) in Denmark and to examine the association between ART use in pregnancy and adverse birth outcomes. A population-based cohort study including all pregnancies among WLWH in Denmark between 2000 and 2019. Data were collected through national registries. Temporal trends of ART use in pregnancy were evaluated. Logistic regression models were used to examine the association of ART use in pregnancy and other risk factors with adverse birth outcomes. In total, 589 pregnancies were included. Combination treatment with a nucleoside reverse transcriptase inhibitor (NRTI) and a protease inhibitor (PI) was the most common ART regimen (96%). ART regimen, PI use in pregnancy and timing of ART initiation were not significantly associated with increased odds of preterm birth, small for gestational age or low birth weight. First-trimester initiation of ART was significantly associated with increased odds of intrauterine growth restriction in the multivariate analysis [adjusted odds ratio (aOR) = 3.78, 95% confidence interval (CI): 1.23-11.59], while first trimester PI use was associated with increased odds of IUGR in the univariate analysis only [OR = 3.24, 95% CI: 1.13-9.30]. Smoking, comorbidity, and maternal HIV RNA ≥ 50 copies/mL were independently associated with increased odds of adverse birth outcomes. Pregnant WLWH living in Denmark are generally well treated with HIV RNA < 50 copies/mL at delivery and NRTI + PI as the most common ART regimen used in pregnancy. Initiation of ART in the first trimester may be associated with poor fetal growth. The association between ART use in pregnancy and adverse birth outcomes may partly be explained by maternal risk factors.
Identifiants
pubmed: 35388607
doi: 10.1111/hiv.13304
pmc: PMC9545374
doi:
Substances chimiques
Reverse Transcriptase Inhibitors
0
RNA
63231-63-0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1007-1018Informations de copyright
© 2022 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.
Références
JAMA Pediatr. 2017 Oct 2;171(10):e172222
pubmed: 28783807
BMC Pregnancy Childbirth. 2015 Oct 08;15:246
pubmed: 26450602
J Infect Dis. 2016 Apr 1;213(7):1051-4
pubmed: 26265779
Lancet HIV. 2022 Feb;9(2):e120-e129
pubmed: 34863352
Int J Epidemiol. 2014 Dec;43(6):1769-9e
pubmed: 25074406
Curr Opin Obstet Gynecol. 2002 Apr;14(2):145-51
pubmed: 11914691
PLoS One. 2018 Jan 19;13(1):e0191389
pubmed: 29351561
Scand J Public Health. 2011 Jul;39(7 Suppl):30-3
pubmed: 21775347
AIDS. 2018 Jan 14;32(2):243-252
pubmed: 29135577
J Infect Dis. 2006 May 1;193(9):1195-201
pubmed: 16586354
AIDS. 2011 Nov 28;25(18):2301-4
pubmed: 21918421
Pediatr Infect Dis J. 2015 Jul;34(7):e169-75
pubmed: 25851070
AIDS. 2017 Feb 20;31(4):553-560
pubmed: 27902507
J Acquir Immune Defic Syndr. 2017 Sep 01;76(1):1-12
pubmed: 28291053
Eur J Clin Microbiol Infect Dis. 2015 Feb;34(2):223-30
pubmed: 25107626
N Engl J Med. 2002 Jun 13;346(24):1863-70
pubmed: 12063370
J Infect Dis. 2015 Jan 1;211(1):10-8
pubmed: 25030058
Lancet Glob Health. 2020 Jan;8(1):e67-e75
pubmed: 31791800
Reprod Health. 2016 Apr 05;13:30
pubmed: 27048501
Subst Use Misuse. 2020;55(7):1165-1172
pubmed: 32100603
J Int AIDS Soc. 2015 Jun 05;18:19933
pubmed: 26051165
Lancet HIV. 2017 Jan;4(1):e21-e30
pubmed: 27864000
Lancet HIV. 2018 Aug;5(8):e457-e467
pubmed: 29958853
J Acquir Immune Defic Syndr. 2012 Mar 1;59(3):287-93
pubmed: 22227490
AIDS. 2017 Jan 14;31(2):213-232
pubmed: 27831952
BMJ Open. 2021 Jul 8;11(7):e044565
pubmed: 34244252
Eur J Epidemiol. 2018 Jan;33(1):27-36
pubmed: 29349587
Clin Infect Dis. 2015 Dec 1;61(11):1715-25
pubmed: 26197844
HIV Med. 2017 Nov;18(10):736-747
pubmed: 28544321
HIV Med. 2020 Feb;21(2):84-95
pubmed: 31603598
HIV Med. 2022 Oct;23(9):1007-1018
pubmed: 35388607
Expert Opin Drug Saf. 2016 Nov;15(11):1501-1513
pubmed: 27552003
BJOG. 2010 Oct;117(11):1399-410
pubmed: 20716250
N Engl J Med. 2018 Sep 6;379(10):979-981
pubmed: 30037297
J Pediatric Infect Dis Soc. 2018 May 15;7(2):e24-e29
pubmed: 29301007
PLoS One. 2011;6(7):e22698
pubmed: 21799935
Clin Infect Dis. 2012 May;54(9):1348-60
pubmed: 22460969
Lancet. 2021 Apr 3;397(10281):1276-1292
pubmed: 33812487
Health Policy. 2018 May;122(5):485-492
pubmed: 29573826
Clin Infect Dis. 2020 May 6;70(10):2168-2177
pubmed: 31271208
Scand J Public Health. 2011 Jul;39(7 Suppl):22-5
pubmed: 21775345
J Virol. 2020 Dec 22;95(2):
pubmed: 33115865
BMJ Open. 2017 Sep 11;7(9):e019022
pubmed: 28893758